For those interested, this is the clinical trial drug I am taking (ACY-241) and the news from ASH this weekend about it. Celgene, who makes Pomalyst (and Revlimid, another big hitter in Multiple Myeloma) just announced in the last few days that they were buying this company. It's bizarre to actually read about a clinical trial you are in. Probably be more bizarre if the announcement was that 90% of the participants had spontaneously combusted or something.
Acetylon Presents Early Phase 1a1b Results for Citarinostat